-- --
Earnings before income taxes 97,995 27,051 3,962
Income tax expense (1,454) (4,662) (683)
Net Income 96,541 22,389 3,279
Less: Net income
attributable to
the noncontrolling
interest (5,384) (5,958) (873)
Net income attributable
to Simcere 91,157 16,431 2,406
Earnings per share
attributable to Simcere:
Basic 0.73 0.15 0.02
Diluted 0.72 0.14 0.02
Earnings per ADS
attributable to Simcere:
Basic 1.46 0.29 0.04
Diluted 1.44 0.29 0.04
Weighted average number
of common shares:
Basic 125,148,011 112,724,593 112,724,593
Diluted 126,261,753 114,929,639 114,929,639
Nine months ended September 30,
2008 2009 2009
RMB RMB USD
Product revenue 1,269,982 1,298,511 190,225
Other revenue 4,256 12,106 1,774
Total revenue 1,274,238 1,310,617 191,999
Cost of materials and
production (242,002) (231,478) (33,910)
Gross profit 1,032,236 1,079,139 158,089
Operating expenses:
Research and development
expenses (52,120) (82,852) (12,137)
Sales, marketing and
distribution expenses (557,188) (702,528) (102
'/>"/>SOURCE Simcere Pharmaceutical Group Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related medicine news :1.
Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin2.
Simcere Pharmaceutical Group Invested Company Obtains Production License for H1N1 Flu Vaccine3.
Simcere Announces Strategic Partnership with Sun Yat-Sen University Cancer Center4.
Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2009 Results and Announces Share Repurchase5.
Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 20096.
Simcere Pharmaceutical Group Files Annual Report on Form 20-F7.
Simcere Pharmaceutical Group Seeking Approval to Manufacture and Sell Influenza Drug zanamivir8.
Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 20089.
Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results10.
Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin11.
Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.